REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07/21/2025
Back to search
Official data from USPTO
QIAGEN - SAMPLE TO OUTCOME
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
QIAGEN - SAMPLE TO OUTCOME
ST13
US500000079264394Class
9, 10, 42, 44
Filing
79264394
Registration
6104156
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
07/22/2025
Trademark type
Word
Nice classes
9, 10, 42, 44
Filing date
05/09/2019
Registration date
07/21/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/21/2020
Last transaction
07/22/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
16
Owner location
DE
Examiner
MAJCHER HARTNETT, MEGAN
Law office
N50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Qiagen GmbH
Representatives
Keith A. Weltsch Scully, Scott, Murphy & Presser, P.C.
Technical classification
Nice Classes
Class 9Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 9
Downloadable and recorded computer software for data and document managementmedical teaching; downloadable and recorded computer software and related downloadable databases for use in preparing and managing nucleic acid and protein assay analysis and for managing quality controlvalidationinterpretationreportingclinical decision supportdata managementintegration with medical recordsphysician portalslaboratory networkingprofessional healthcare and trial matching services all related to molecular and genomic analysis; downloadable and recorded computer softwareevidence-based decision support software used as an aid in the interpretation of variants observed in genomic sequencing data; downloadable and recorded computer software for evaluation of genomic variants in the context of software for searching and allocating published biomedical literatureprofessional association guidelinespublicly available databases and annotationsdrug labelsand/or clinical-trials; downloadable and recorded computer software for preparinginterpretation and managing of bioinformatics analysesoptionally combined with data managementgraphical viewing and output options; downloadable and recorded computer programs and software for biological data mining; downloadable and recorded computer programs and software for developing bioinformatics database for others; bio-chips for research or scientific purposes; DNA-chips; RNA-chips; next-generation sequencing (NGS) data processor; bioinformatics data processor; computer hardware and downloadable and recorded computer software for collectingstoringanalyzingvisualizinginterpreting bioinformaticsgenomicsphenomics data sets; computer hardware and downloadable and recorded computer software for the monitoring of pathogens; downloadable computer databases for bioinformaticsgenomicsphenomicsmicrobiomemetagenomicsorganism-and -pathogen-specific genotype recordsorganism and pathogen-specific phenotype information; downloadable and recorded computer software for use in the integrationanalysis and visualization of biomedically relevant information allowing users to explore compoundtargetassaybiological pathway and disease information; downloadable and recorded computer software and databases for the analysis of genomesexomestargeted ampliconstranscriptomesepigenetic NGS sequencing data; downloadable and recorded computer softwaresoftware development toolsvisualization software modulesfor analysisdiscoveryverificationvalidation of disease biomarkers
Class 10
Medical diagnostic testing instruments for processing and analysis of genetic samples primarily for single-cell genomictranscriptomicproteomic analysis; medical and diagnostic apparatus for testing DNA and RNA samplesusing gene expression testsgene expression profiling assaysgenetic information and dataprotein biomarkersclinical dataand/or demographic information; testing apparatus for medical purposes for testing DNA and RNA samples sold as a unit with downloadable bioinformatics and machine learning algorithm software and medical data software to support treatment decisions; medical testing apparatus for testing DNA and RNA samples and quantifying biomarker levels and relative expression of host response genes; medical apparatus and instruments for detecting tumor cancerheredity and genetic diseases; medical testing apparatus for samples of body fluidstissue and organs; genome machine for medical purposesapparatus for DNA and RNA medical testing; diagnostic apparatus for the detection of cancergenetic or heredity diseases
Class 42
Providing temporary use of online non-downloadable software for use in collectingorganizing and managing data on bioinformaticsgenomicsphenomicsmicrobiomemetagenomics applications; hosting of computer databases featuring information relating to bioinformaticsgenomicsphenomicsmicrobiomemetagenomicsorganism- and pathogenspecific genotype recordsorganism and pathogen-specific phenotype information; consulting relating to computer programming for acquiringcreatingsharingmanagingmininganalyzingvisualizinginterpreting and applying genomics and phenomics records; providing scientific analysis in the field of next generation sequencing (NGS)the analysis and interpretation of genomic data obtained from patients; providing an onlinenon-downloadable computer software platform for purposes of storing and providing information about an individual's disease profile and genomic changes to enable physicians and healthcare professionals to optimize treatment in clinical practice; providing temporary use of on-line nondownloadable software and applications for genome analysisdeveloping personal treatment strategies for patients with diagnosed cancer and other diseases or disorders; conducting early evaluations in the field of new pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; providing information about medical and scientific research in the field of bioinformatics to enable physicians and healthcare professionals to optimize treatment in clinical practice; computer programming services for medical reportingfor creatingsharingmanagingmininganalyzingvisualizinginterpreting and applying genomics and phenomics records; scientific research servicesproviding information relating to research in the field of specific molecular and genomic sciences for analytical and clinical purposesfor the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; providing scientific advice in the fields of cancer biologycancer treatmentpharmaceutical side effectsgenomicscancer medicine and translational medicine; providing scientific analysis in the field of next generation sequencing (NGS)the analysis and interpretation of genomic data obtained from patients with cancer and other diseases and disorders
Class 44
Providing medical information and medical advice in the fields of retrievalintegrationcorrelationanalysis and interpretation of genomic datasequencing data and molecular datadiseasesbiomarkersdrug protocolsdrug interactionsclinical profilesmedical and health informationrecords or data and patient-specific datamolecular test resultsclinical trial data; medical consulting services in the fields of healthmedical carebiotechnologybioinformaticslife sciencespharmaceuticals and medicine; providing medical information in the fields of healthhealthcarelife sciencesbiotechnologypharmaceuticals and pharmaceutical safetybioinformaticsgenetic testing for medical purposes; medical consulting services with respect to the treatment and diagnosis of individuals; providing medical information on drug safety and drug compatibility in relation to therapy and the treatment of individuals; medical consulting services in the fields of diagnostics and patient treatment and treatment protocols; medical consulting services in the field of genomics and biological sequence processing and analysis for medical diagnosis and treatment purposes; providing medical information for the purposes of medical diagnosis and treatment in the field of molecular genetics; identification and testing of DNA samples for health care purposes; health care servicesmedical genomics and data science consultancy to provide optimal health and disease prevention or treatment to patients; providing health information relating to genetics and diagnostics via the Internet; bioinformatics analysis for medical diagnostic and personalized treatment purposes; nucleic acid analysis and screening for medical diagnostic and treatment purposes
Publications
History of USPTO decisions and trademark events.
27 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/05/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/12/2020
FIMP
FINAL DISPOSITION PROCESSED
11/12/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/21/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
07/21/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/05/2020
PUBO
PUBLISHED FOR OPPOSITION
05/05/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/15/2020
ALIE
ASSIGNED TO LIE
04/02/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/25/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
03/25/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/25/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
03/25/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/25/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/05/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/04/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/04/2020
RFNT
REFUSAL PROCESSED BY IB
09/28/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/06/2019
RFRR
REFUSAL PROCESSED BY MPU
09/06/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/14/2019
CNRT
NON-FINAL ACTION WRITTEN
08/13/2019
MAFR
APPLICATION FILING RECEIPT MAILED
08/13/2019
DOCK
ASSIGNED TO EXAMINER
08/09/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/09/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/01/2019
Continuous trademark protection
Get notified about every new filing that threatens QIAGEN - SAMPLE TO OUTCOME or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.